

TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



		& Microbiology)		: Yugam Chopra MD (Pathology) Consultant Pathologist	
NAME AGE/ GENDER COLLECTED BY REFERRED BY BARCODE NO. CLIENT CODE. CLIENT ADDRESS	: Mrs. MANPREET KAUR : 34 YRS/FEMALE : : Dr. A.K.JINDAL (AMBALA CITY) : 01526599 : KOS DIAGNOSTIC LAB : 6349/1, NICHOLSON ROAD, AMI		PATIENT ID REG. NO./LAB NO. REGISTRATION DATE COLLECTION DATE REPORTING DATE	: 1781693 <b>: 012503070010</b> : 07/Mar/2025 08:55 AM : 07/Mar/2025 08:56AM : 07/Mar/2025 12:08PM	
Test Name		Value	Unit	Biological Reference interval	
CHOLESTEROL TOT by CHOLESTEROL OX	TAL: SERUM		<b>FRY/BIOCHEMIST</b> <b>FILE : BASIC</b> mg/dL	<b>TRY</b> OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR =	
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)		81.64	mg/dL	HIGH CHOLESTEROL: > OR = 240.0 OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0	
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION		39.6	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 60.0 HIGH HDL: > OR = 60.0	
LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY		105.87	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0	
NON HDL CHOLEST by CALCULATED, SPE		122.2	mg/dL	VERT HIGH. > OK = 190.0 OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0	
VLDL CHOLESTERC		16.33	mg/dL	0.00 - 45.00	
TOTAL LIPIDS: SER by CALCULATED, SPE	CTROPHOTOMETRY	405.24	mg/dL	350.00 - 700.00	
CHOLESTEROL/HD	L RATIO: SERUM ctrophotometry	4.09	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0	

KOS Diagnostic Lab (A Unit of KOS Healthcare)

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: Ilnd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com

 www.koshealthcare.com
 www.koshealthcare.com



Page 1 of 2





	Dr. Vinay ChopraDr. Yugam ChopraMD (Pathology & Microbiology)MD (Pathology)Chairman & Consultant PathologistCEO & Consultant Pathologist					
NAME	: Mrs. MANPREET KAUR					
AGE/ GENDER	: 34 YRS/FEMALE		PATIENT ID	: 1781693		
COLLECTED BY	:		REG. NO./LAB NO.	: 012503070010		
<b>REFERRED BY</b>	: Dr. A.K.JINDAL (AMBALA CITY)		<b>REGISTRATION DATE</b>	: 07/Mar/2025 08:55 AM		
BARCODE NO.	: 01526599		<b>COLLECTION DATE</b>	: 07/Mar/2025 08:56AM		
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 07/Mar/2025 12:08PM		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AM	BALA CANT	Т			
Test Name		Value	Unit	<b>Biological Reference interval</b>		
				MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0		
LDL/HDL RATIO: SERUM by calculated, spectrophotometry		2.67	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0		
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY2		2.06 <sup>L</sup>	RATIO	3.00 - 5.00		

## **INTERPRETATION:**

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

End Of Report \*\*\*





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

